Meeting
2021 ASCO Annual Meeting
First results of a randomized phase IB study comparing nivolumab/ipilimumab with or without CBM-588 in patients with metastatic renal cell carcinoma.
Authors
Luis A Meza
City of Hope Comprehensive Cancer Center, Duarte, CA
Luis A Meza , Nazli Dizman , Paulo Gustavo Bergerot , Tanya B. Dorff , Yung Lyou , Paul Henry Frankel , Valerie Mira , Marian Llamas , Joann Hsu , Zeynep Busra Zengin , Nicholas Salgia , Sabrina Salgia , Jasnoor Malhotra , Neal Shiv Chawla , Alex Chehrazi-Raffle , John D Gillece , Lauren J Reining , Jeffrey M. Trent , Sarah K Highlander , Sumanta K. Pal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT03829111
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4513)
DOI
10.1200/JCO.2021.39.15_suppl.4513
Abstract #
4513
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Clinical outcomes of patients with metastatic renal cell carcinoma who discontinued nivolumab +/- ipilimumab therapy electively or due to toxicity.
First Author: Jessica Heejin Yoo
Poster
2024 ASCO Genitourinary Cancers Symposium
Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).
First Author: Regina Barragan-Carrillo
Poster
2023 ASCO Annual Meeting
Association of neutrophil to eosinophil ratio (NER) with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with first-line (1L) immune checkpoint inhibitors (ICI) –based regimens.
First Author: Marc Eid
Poster
2023 ASCO Genitourinary Cancers Symposium
Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC).
First Author: Nazli Dizman